RxDoctor Payments Data

Yeshika Sharma, MD

Gastroenterology · Dallas, TXNPI 1679987994

Payments from drug & device makers

$24,188in general payments, 2019–2025

Across 50 payments — averaging $483.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$15K
  • Novo Nordisk$8K
  • AbbVie$235
  • Ipsen Biopharmaceuticals, Inc$169
  • Regeneron Healthcare Solutions, Inc.$125
  • Sanofi$108
  • plus $316 from 8 others

What the payments were for

  • Consulting fees$3,62815%
  • Speaking & faculty fees$18,26576%
  • Travel & lodging$6993%
  • Food & beverage$1,5977%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,188 in reported general payments places this provider in the 80th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$34,363
Medicare patients
139
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin17$52,494
VemlidyTenofovir Alafenamide19$26,161
Envarsus XrTacrolimus19$24,018
Tacrolimus141$10,228
Valganciclovir Hcl15$7,533
Mycophenolate Mofetil110$7,452
Ursodiol36$4,696
Entecavir42$2,604
Sirolimus12$1,906
Lactulose18$593
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl20$267
Pantoprazole Sodium30$212
Torsemide19$204
Nifedipine ErNifedipine15$175
Azathioprine14$149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$25$52,49417 claims
GileadVemlidy$28$26,16119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →